Guido Marcucci


Affiliation: The Ohio State University
Country: USA


  1. Marcucci G, Radmacher M, Mrozek K, Bloomfield C. MicroRNA expression in acute myeloid leukemia. Curr Hematol Malig Rep. 2009;4:83-8 pubmed publisher
    ..This article reviews recent studies that were focused on the alterations of microRNA expression in AML and their diagnostic and prognostic significance. ..
  2. Marcucci G, Radmacher M, Maharry K, Mrozek K, Ruppert A, Paschka P, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1919-28 pubmed publisher
    ..A role of microRNAs in cancer has recently been recognized. However, little is known about the role of microRNAs in acute myeloid leukemia (AML)...
  3. Marcucci G, Maharry K, Radmacher M, Mrozek K, Vukosavljevic T, Paschka P, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008;26:5078-87 pubmed publisher
    ..The gene and miRNA expression profiling provided insights into leukemogenesis of the CN-AML molecular high-risk group, indicating that CEBPA mutations are associated with partial erythroid differentiation. ..
  4. Marcucci G, Metzeler K, Schwind S, Becker H, Maharry K, Mrozek K, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30:742-50 pubmed publisher
    ..Low accuracy of gene- and microRNA-expression signatures in predicting DNMT3A mutation status suggested that the role of these mutations in AML remains to be elucidated. ..
  5. Marcucci G, Maharry K, Metzeler K, Volinia S, Wu Y, Mrozek K, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol. 2013;31:2086-93 pubmed publisher
    ..The availability of emerging compounds with antagonistic activity to microRNAs in the clinic provides the opportunity for future therapeutic targeting of miR-155 in AML. ..